Tag Archives: Jay Flatley

Business, Finance, Occupation & Industry

Illumina to Announce First Quarter 2013 Financial Results on Monday, April 22, 2013

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Illumina to Announce First Quarter 2013 Financial Results on Monday, April 22, 2013

SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc. (NAS: ILMN) today announced that it will issue results for first quarter 2013 following the close of market on Monday, April 22, 2013.

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time), Jay Flatley, President and Chief Executive Officer, Marc Stapley, Senior Vice President and Chief Financial Officer, and Christian Henry, Senior Vice President and General Manager, Genomic Solutions, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Monday, April 22, 2013. Interested parties may listen to the call by dialing 888.679.8033 (passcode: 58226131), or if outside North America, by dialing +1.617.213.4846 (passcode: 58226131). Individuals may access the live teleconference in the Investor Relations section of Illumina’s web site under the “Company” tab at www.illumina.com.

A replay of the conference call will be available from 4:00 pm Pacific Time (7:00 pm Eastern Time) on April 22, 2013 through April 29, 2013 by dialing 888.286.8010 (passcode: 31374623), or if outside North America, by dialing +1.617.801.6888 (passcode: 31374623).

About Illumina

Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article Illumina to Announce First Quarter 2013 Financial Results on Monday, April 22, 2013 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Illumina Technology Enables Findings of the Collaborative Oncological Gene-Environment Study (COGS)

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Illumina Technology Enables Findings of the Collaborative Oncological Gene-Environment Study (COGS)

Custom iSelect® Genotyping Array Designed in Collaboration with Consortia to Advance Understanding of Cancer; Study Results Published Today

SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc. (NAS: ILMN) announced that its iCOGS custom array was used to identify genetic variants related to breast, ovary and prostate cancer as part of the Collaborative Oncological Gene-Environment Study (COGS), the results of which were published today in Nature Genetics and other leading journals.1 Developed in collaboration with four large consortia2 involved in the study, the iCOGS array enables significant advances in understanding the genetic basis of cancer.

Specifically, the iCOGS array identifies single-nucleotide polymorphisms (SNPs) across selected regions of DNA associated with cancer. Its 200,000 SNPs were drawn from previous genome-wide association studies of the different cancer types and subtypes; associations with disease survival or other traits that are associated with risk of cancer; and functional candidates. The technology was used to test more than 200,000 individuals participating in the COGS.

“This groundbreaking study demonstrates how genomic technology is advancing cancer research,” said Jay Flatley, Illumina’s President and Chief Executive Officer. “We applaud the efforts of the consortia, and are pleased the iCOGS array played a role in enabling this research that ultimately will help patients.”

The COGS findings include a striking increase in the number of genetic associations for breast, ovarian and prostate cancer – nearly doubling the number of known susceptibility regions. The findings also provide insights into the differences between subtypes of cancer, including those revealed from comparisons of Estrogen Receptor+ and Estrogen Receptor- breast cancers, as well as the pathways and mechanisms involved in susceptibility to these common cancers.

David Bentley, Vice President and Chief Scientist at Illumina added, “The partnership of the consortia and their work with us unified an enormous depth of knowledge to create a single, specialized array for application to the entire study cohort. Ultimately, we believe the results of the COGS have significant implications in the understanding and management of cancer.”

To read the papers, visit: http://www.nature.com/icogs/.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Illumina Announces Favorable Outcome of Its Patent Litigation Against Life Technologies, Inc.

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Illumina Announces Favorable Outcome of Its Patent Litigation Against Life Technologies, Inc.

SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc. (NAS: ILMN) announced today that District Court Judge Cathy Ann Bencivengo of the U.S. District Court for the Southern District of California granted Illumina’s motion for summary judgment that its sequencing systems do not infringe U.S. Patent Nos. 5,616,478; 5,958,698 and 6,001,568, being asserted by Life Technologies Corporation in a lawsuit filed against Illumina in 2009. The Court ruled that, “Life Tech cannot establish, as a matter of law, that the accused Illumina systems infringe” the patents.

Jay Flatley, Illumina’s President and CEO, stated, “We are obviously very pleased with the favorable outcome of this suit. Since Life Technologies filed this patent infringement suit against Illumina in 2009, we have consistently believed and strongly argued that our sequencing technology does not infringe any of the patents Life Technologies asserted against us in this case. The federal court’s ruling has now vindicated our position. While our policy is to respect the valid and enforceable intellectual property rights of others, and take licenses where appropriate, this case demonstrates we are determined to defend vigorously any unfounded claims of infringement.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Illumina Announces Outcome of Its Patent Litigation Against Syntrix Biosystems, Inc.

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Illumina Announces Outcome of Its Patent Litigation Against Syntrix Biosystems, Inc.

SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc. (NAS: ILMN) today announced that a federal jury in Tacoma, Washington found that Illumina’s BeadChip array product infringed U.S. Patent No. 6,951, 682, asserted by Syntrix Biosystems, Inc. The federal jury ordered Illumina to pay approximately $96 million in damages to Syntrix based on a royalty rate of six percent for BeadChip products sold by Illumina from 2005 through May 2012. United States District Court Judge Benjamin H. Settle, however, dismissed from the case claims that Illumina’s alleged infringement was willful and that Illumina misappropriated Syntrix’s trade secrets. The Syntrix patent expires on September 17, 2019.

Illumina continues to believe that Syntrix’s claims are without merit. Illumina intends to file post-trial motions asking the court to vacate the jury’s finding and to rule as a matter of law that the BeadChip does not infringe Syntrix’s patent.

Jay Flatley, Illumina’s President and CEO, stated, “We strongly disagree with this verdict and plan to appeal the present finding of infringement. In the meantime, we will continue to sell the products that are the subject of this suit and no damages will be payable to Syntrix until all appropriate appeals have been taken, which may take a number of years.” Mr. Flatley continued, “Our BeadChip products are based on Dr. David Walt‘s technology that was licensed from Tufts University when Illumina was founded in 1998. Like many other companies, we respect the valid and enforceable intellectual property rights of others. Consistent with our policy, we believe we acted properly with respect to the Syntrix ‘682 patent. We continue to feel very strongly about our position that Syntrix’s allegations are without merit and that, ultimately, our position will be vindicated.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

…read more
Source: FULL ARTICLE at DailyFinance